Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14099477 | 0.87 | MAPT (0.68) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL20484216 | 0.84 | MAPT (0.48) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL28148463 | 0.84 | KMT2A (0.53) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL13964086 | 0.83 | NPC1 (0.62) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL8596871 | 0.83 | LMNA (0.67) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL9535747 | 0.81 | LMNA (0.60) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL2222503 | 0.81 | MEN1 (0.56) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL9690882 | 0.81 | MAPT (0.68) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL7369725 | 0.81 | MAPT (0.68) | NPC1MAPTRAB9APKMLMNA | |
| SCHEMBL11016312 | 0.80 | MEN1 (0.63) | NPC1MAPTRAB9APKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11600791-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3936512-A1 | PYRIDYL CARBENE PHOSPHORESCENT EMITTERS | Universal Display Corporation (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3936512-A1 | PYRIDYL CARBENE PHOSPHORESCENT EMITTERS | Universal Display Corporation (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3424935-B1 | IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3424935-B1 | IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210050530-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210050530-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-02-18 | — | — | US | disclosed |
| US-10873038-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-12-22 | — | — | US | disclosed |
| US-10873038-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190109287-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-04-11 | — | — | US | disclosed |
| US-6420359-B1 | 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-03-07 | — | — | US | disclosed |
| WO-2001096338-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-20 | — | — | WO | disclosed |
| EP-0429987-B1 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5705499-A | VIRICIDES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5620974-A | ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0767172-A1 | 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5366972-A | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0429987-A2 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0272533-A2 | Substituted phenoxypyridines | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210050530-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | NUDC, NCL, NDC1 | NPC1 3431/4885MAPT 608/4885RAB9A 1436/4885 |
| US-10873038-B2 | Organic electroluminescent materials and devices | NUDC, NCL, NDC1 | NPC1 3431/4885MAPT 608/4885RAB9A 1436/4885 |
| US-20190109287-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | NUDC, NCL, NDC1 | NPC1 3431/4885MAPT 608/4885RAB9A 1436/4885 |
| US-20020028807-A1 | Non-nucleoside reverse transcriptase inhibitors | REV1, POLR2H, POLR2E | NPC1 962/4885MAPT 3668/4885RAB9A 3373/4885 |
| US-11600791-B2 | Organic electroluminescent materials and devices | NUDC, NCL, NDC1 | NPC1 3431/4885MAPT 608/4885RAB9A 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.